Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Journal of Neuro-oncology
Tobias WalbertVictor A Levin

Abstract

We evaluated the efficacy of temozolomide (TMZ) or lomustine (CCNU) in combination with 6-thioguanine, capecitabine, and celecoxib for the treatment of recurrent high-grade glioma. Forty-three patients with recurrent glioblastoma and 31 patients with recurrent anaplastic glioma (AG) were enrolled in this open-label, non-comparative study. Patients previously treated with TMZ received CCNU while all others received TMZ; all patients received 6-thioguanine, capecitabine, and celecoxib. Endpoints were 12-month progression-free survival (PFS) for patients with AG, 6-month PFS for patients with glioblastoma, duration of PFS, and MRI-based objective response rates. Results from the TMZ and CCNU treatment arms were combined in the final analysis because there was no statistically significant difference between them. Thirty-eight patients with glioblastoma were treated with the lomustine-based regimen, and five received the TMZ-based regimen. For the 43 glioblastoma patients, the objective response rate was 12 and 33% had stable disease; the 6-month PFS was 14% and median overall survival 32 weeks. For the 31 AG patients, the combined objective response rate was 26 and 42% had stable disease; the 12 month PFS was 44%. Treatment was rea...Continue Reading

References

May 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V A Levin, M D Prados
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·M D PradosC B Wilson
Jan 11, 1991·Cancer Chemotherapy and Pharmacology·A M WangS C Schold
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Jan 9, 1998·International Journal of Radiation Oncology, Biology, Physics·M D PradosC B Wilson
Sep 14, 1999·Acta Neuropathologica·M H DeiningerR Meyermann
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T WongW K Yung
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K YungV A Levin
Jun 4, 2004·The Journal of Investigative Dermatology·Traci A WilgusTatiana M Oberyszyn
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 24, 2007·International Journal of Cancer. Journal International Du Cancer·Takanobu IrieNorio Hayashi
Jun 10, 2008·Current Medicinal Chemistry·Rainer GoernePeter Hau
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine

❮ Previous
Next ❯

Citations

Mar 29, 2011·Cancer Chemotherapy and Pharmacology·Athanassios P Kyritsis, Victor A Levin
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick
Sep 1, 2012·CNS Oncology·Victor Alan Levin
Jun 6, 2012·Journal of Biomedicine & Biotechnology·C Vilos, L A Velasquez
Jul 22, 2014·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Susan V EllorNicholas G Avgeropoulos
Feb 13, 2016·PloS One·Corinna SeligerMichael F Leitzmann
Apr 22, 2014·Oncogene·C J EdenR J Gilbertson
May 6, 2015·Expert Review of Neurotherapeutics·Emilie Le RhunMarc C Chamberlain
Apr 18, 2014·Journal of Neuro-oncology·Jeffrey J OlsonUNKNOWN AANS/CNS Joint Guidelines Committee
Apr 8, 2011·Expert Review of Neurotherapeutics·Tobias Walbert, Tom Mikkelsen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.